Newman Ferrara LLP recently announced that the firm is conducting an investigation on behalf of shareholders of OncoMed Pharmaceuticals Inc. (“OncoMed” or the “Company”) (NASDAQ:OMED) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”).
@NewmanFerrara Announces Corporate Governance Investigation of OncoMed Pharmaceuticals Inc. OMED
Tweet this
OncoMed, headquartered in Redwood City, CA, is a clinical-stage, biopharmaceutical company. Newman Ferrara’s investigation focuses on decisions made by the Board, without shareholder approval, the result of which significantly diminish shareholder value and do not benefit the Company. Considering the Company’s lackluster performance since its 2013 initial public offering, it is clear that the Board lacks the ability to fairly assess and oversee the Company’s direction and leadership.
Current OncoMed stockholders seeking more information on this matter are invited to contact Newman Ferrara attorneys Jeffrey Norton (jnorton@nfllp.com) or Ryan Jerome (rjerome@nfllp.com) to discuss this investigation and their rights.
Newman Ferrara maintains a multifaceted practice based in New York City with attorneys specializing in complex commercial and multi-party litigation, securities fraud and shareholder litigation, consumer protection, civil rights, and real estate. For more information, please visit the firm website at www.nfllp.com.